ADAR1 Capital Management LLC Has $385,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

ADAR1 Capital Management LLC lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 85.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,683 shares of the company's stock after selling 101,055 shares during the quarter. ADAR1 Capital Management LLC owned about 0.06% of Dianthus Therapeutics worth $385,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth $556,000. Barclays PLC grew its stake in Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company's stock worth $1,141,000 after buying an additional 33,185 shares in the last quarter. State Street Corp increased its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after buying an additional 413,425 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock valued at $4,543,000 after buying an additional 97,362 shares during the period. Finally, Wellington Management Group LLP acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $1,473,000. Institutional investors own 47.53% of the company's stock.

Analysts Set New Price Targets

DNTH has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim reiterated a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Trading Up 12.9 %

DNTH traded up $2.01 on Friday, reaching $17.61. The stock had a trading volume of 304,304 shares, compared to its average volume of 259,482. The company has a market capitalization of $565.72 million, a price-to-earnings ratio of -7.04 and a beta of 1.62. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The firm has a 50-day moving average of $20.67 and a 200-day moving average of $23.38.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.